A nanocarrier platform for targeted therapies
Nanomedx has developed a universal nanocarrier platform that enables delivery of biointeractive cargo across a range of biomedical and therapeutic applications.
One platform, multiple applications
A single core technology, more than one use case
Nanomedx's nanoparticle carrier platform adapts across clinical applications.
Technology
Built on plasma nanoscience
Nanomedx's nanocarrier platform is synthesized, manufactured, and validated in-house
Plasma-synthesized nanocarriers
Carbon-based nanoparticles are synthesized by plasma polymerization, allowing biointeractive cargo to be immobilized directly on the particle surface without chemical linkers.
Engineered for GMP manufacturing
A purpose-built manufacturing apparatus, covered by its own patent family, is designed to take production from lab-scale synthesis to GMP-grade output.
Peer-reviewed safety data
Toxicity and biosafety have been characterised in peer-reviewed studies, and the platform has been used to deliver growth factors, dual siRNA, and biologic cargo in vivo.
Protected by four patent families
IP spans the core nanoparticle platform, the manufacturing process, biologic conjugation chemistry, and application-specific delivery devices.
Leadership & Team
Meet the team building Nanomedx
Leadership
Bede O'Connor
CEO & Director
Prof. Steven Wise
CSO & Director
Co-Founder
Jeff Reid
Investor & Director
Team
Dr. Richard Tan
Head of Cardiovascular Programs
Co-Founder
Danyon Munro
Regulatory & Quality Manager
Dr. Timothy Mitchell
Lead Engineer
Chien Hung
Biological Scientist
Co-FounderIn partnership with
Interested in the Nanomedx platform?
Get in touch to discuss partnership, licensing, or investment opportunities.